Eosinopenia and neutrophil-to-lymphocyte count ratio as prognostic factors in exacerbation of COPD.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
26 02 2021
26 02 2021
Historique:
received:
22
06
2020
accepted:
16
02
2021
entrez:
27
2
2021
pubmed:
28
2
2021
medline:
16
12
2021
Statut:
epublish
Résumé
Exacerbations of Chronic Obstructive Pulmonary Disease (AECOPDs) are one of the most important clinical aspects of the disease, and when requiring hospital admission, they significantly contribute to mortality among COPD patients. Our aim was to assess the role of eosinopenia and neutrophil-to-lymphocyte count (NLR) as markers of in-hospital mortality and length of hospitalization (LoH) among patients with ECOPD requiring hospitalization. We included 275 patients. Eosinopenia was associated with in-hospital deaths only when coexisted with lymphocytopenia, with the specificity of 84.4% (95% CI 79.6-88.6%) and the sensitivity of 100% (95% CI 35.9-100%). Also, survivors presented longer LoH (P < 0.0001). NLR ≥ 13.2 predicted in-hospital death with the sensitivity of 100% (95% CI 35.9-100%) and specificity of 92.6% (95% CI 88.8-95.4%), however, comparison of LoH among survivors did not reach statistical significance (P = 0.05). Additionally, when we assessed the presence of coexistence of eosinopenia and lymphocytopenia first, and then apply NLR, sensitivity and specificity in prediction of in-hospital death was 100% (95% CI 35.9-100) and 93.7% (95% CI 90.1-96.3), respectively. Moreover, among survivors, the occurrence of such pattern was associated with significantly longer LoH: 11 (7-14) vs 7 (5-10) days (P = 0.01). The best profile of sensitivity and specificity in the prediction of in-hospital mortality in ECOPD can be obtained by combined analysis of coexistence of eosinopenia and lymphocytopenia with elevated NLR. The occurrence of a such pattern is also associated with significantly longer LoH among survivors.
Identifiants
pubmed: 33637803
doi: 10.1038/s41598-021-84439-8
pii: 10.1038/s41598-021-84439-8
pmc: PMC7910289
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
4804Références
World J Cardiol. 2014 May 26;6(5):338-44
pubmed: 24944763
Heart Surg Forum. 2016 Apr 18;19(2):E088-93
pubmed: 27146240
Clin Chem Lab Med. 2018 Mar 28;56(4):669-680
pubmed: 29220883
Respirology. 2010 Jan;15(1):165-7
pubmed: 19947999
Nat Immunol. 2004 Sep;5(9):927-33
pubmed: 15300249
Intensive Care Med. 2011 Jul;37(7):1136-42
pubmed: 21369810
Immunol Cell Biol. 2010 Mar-Apr;88(3):250-6
pubmed: 20065995
J Clin Invest. 1981 Jan;67(1):28-36
pubmed: 7005265
Int J Chron Obstruct Pulmon Dis. 2017 Aug 03;12:2285-2290
pubmed: 28814856
Am J Med. 1981 Nov;71(5):773-8
pubmed: 7304648
Trends Immunol. 2010 Sep;31(9):354-61
pubmed: 20691634
Science. 2003 Apr 11;300(5617):337-9
pubmed: 12690201
Nature. 1998 Jun 4;393(6684):480-3
pubmed: 9624005
Annu Rev Immunol. 2004;22:599-623
pubmed: 15032590
Nature. 2013 Oct 10;502(7470):245-8
pubmed: 24037376
Lancet. 2007 Sep 1;370(9589):786-96
pubmed: 17765528
J Stroke Cerebrovasc Dis. 2017 Oct;26(10):2248-2255
pubmed: 28733122
Allergy. 2013 Jul;68(7):829-35
pubmed: 23742015
J Exp Med. 2002 Oct 7;196(7):957-68
pubmed: 12370257
Maedica (Bucur). 2015 Mar;10(1):10-3
pubmed: 26225143
Semin Immunol. 2004 Jun;16(3):171-7
pubmed: 15130501
Am J Respir Crit Care Med. 1998 May;157(5 Pt 1):1418-22
pubmed: 9603117
Am J Respir Crit Care Med. 2015 Aug 15;192(4):428-37
pubmed: 26039632
Nat Immunol. 2016 Jan;17(1):43-4
pubmed: 26681462
Nature. 2007 Feb 8;445(7128):648-51
pubmed: 17187052
Infect Dis (Lond). 2018 Mar;50(3):163-174
pubmed: 29070003
Nat Immunol. 2013 Jun;14(6):536-42
pubmed: 23685824
Blood. 2009 May 21;113(21):5134-43
pubmed: 19293427
COPD. 2015;12(6):636-42
pubmed: 26263035
Crit Care. 2008;12(2):R59
pubmed: 18435836
J Immunol. 2017 Feb 15;198(4):1627-1637
pubmed: 28069805
Anaesth Intensive Care. 2013 Mar;41(2):231-41
pubmed: 23530790